ReviewF1000Research2017

Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate.

Takumi Satoh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.